Related Experiment Videos
Routine monitoring of gentamicin serum concentrations in pediatric patients with normal renal function is unnecessary
1Cook Children's Medical Center, Fort Worth, TX 76104, USA.
Insights
Routine monitoring of gentamicin levels is not necessary for pediatric patients over three months old with normal kidney function receiving standard doses. This approach aids healthcare cost containment by avoiding unnecessary laboratory tests.
Area of Science:
- Pharmacology
- Pediatric Medicine
- Clinical Pharmacy
Background:
- Healthcare systems face increasing pressure for cost containment.
- Optimizing antibiotic therapy is crucial for patient outcomes and resource management.
- Gentamicin is a commonly used antibiotic in pediatric populations.
Purpose of the Study:
- To evaluate the necessity of routine gentamicin concentration monitoring in pediatric patients.
- To assess if standard dosing achieves therapeutic levels without routine checks.
- To inform clinical practice guidelines regarding gentamicin monitoring.
Main Methods:
- A single-institution study was conducted in a 225-bed pediatric teaching hospital.
- 150 pediatric patients (3 months to 15 years) with normal renal function were included.
- Therapeutic gentamicin concentrations were defined based on clinical response and laboratory parameters.
Main Results:
- Patients received standard gentamicin doses (2.51 mg/kg IV q8h) with mean peak of 6.1 mcg/mL and trough of 0.5 mcg/mL.
- 96% achieved therapeutic peak concentrations, and 100% had trough levels below 2 mcg/mL.
- No patients required dosage adjustments due to lack of clinical response or renal function changes.
Conclusions:
- Routine monitoring of gentamicin concentrations is not supported in pediatric patients over three months old with normal renal function receiving standard doses.
- This finding can contribute to cost savings within healthcare systems.
- Clinical practice can be refined to focus on patients with risk factors for altered gentamicin pharmacokinetics.
Objective:
Due to increasing demands for cost containment within the healthcare system, we evaluated the need for routine gentamicin concentrations (i.e., peak and trough with third dose).
Design:
Single-institution study performed concurrently with hospitalization.
Setting:
A 225-bed pediatric teaching hospital.
Participants:
The study population consisted of 150 hospitalized pediatric patients (53% medicine, 47% surgical patients) from 3 months to 15 years old with normal serum creatinine.
Outcome Measures:
If the administered dose produced diagnoses-appropriate peak concentrations of at least 4 micrograms/mL or 5 micrograms/mL in bacteremia/septicemia and at least 6 micrograms/mL or 8 micrograms/mL in patients with pneumonia if trough serum gentamicin concentrations were less than 2 micrograms/mL, if the patient was noted by the attending physician to be clinically responding as well as objectively having a decreased white blood cell count and was afebrile, and if there was not an increase of 0.5 mg/dL or more in serum creatinine during the course of therapy.
Results:
Patients received a mean dose of gentamicin 2.51 +/- 0.14 mg/kg i.v. q8h, which resulted in a mean peak concentration of 6.1 +/- 1.7 micrograms/mL (range 2.4-11.7) and a mean trough concentration of 0.5 +/- 0.3 microgram/mL (range 0.1-1.8). Peak and trough concentrations were at least 4 micrograms/mL and less than 2 micrograms/mL in 96% and 100% of patients, respectively. No patient required a dosage change due to lack of clinical response.
Conclusions:
Our data do not support the routine monitoring of gentamicin concentrations in pediatric patients older than 3 months of age who are receiving appropriate standard doses of gentamicin and have normal renal function.